This company has been acquired
Blueprint Medicines Dirección
Dirección controles de criterios 2/4
El CEO de Blueprint Medicines es Kate Haviland , nombrado en Apr 2022, tiene una permanencia de 3.25 años. compensación anual total es $13.48M, compuesta por 6.1% salario y 93.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $9.14M. La antigüedad media del equipo directivo y de la junta directiva es de 5 años y 10.2 años, respectivamente.
Información clave
Kate Haviland
Chief Executive Officer (CEO)
US$13.5m
Compensación total
| Porcentaje del salario del CEO | 6.09% |
| Permanencia del CEO | 3.3yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 5yrs |
| Promedio de permanencia en la Junta Directiva | 10.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade
Summary Sanofi's deal to acquire Blueprint was announced on June 2nd ,for an initial amount of $9.1bn, or $129 per share. Sanoi will acquire Blueprint's approved drug for mastocytosis Aykavit, which earned $150m last quarter, and could reach $2bn in revenues by 2030. There are contingent value rights that may pay up to $6 per share based on a pipeline drug, BLU-808, achieving certain milestones. Sanofi had the money and the desire to do the deal, and the price paid will likely satisfy Bluerprint shareholders - up >600% since IPO. This is, therefore, a good deal for Sanofi, and Blueprint, and could kick off a bull run on stock, as Aykavit will be immediately revenue accretive. Read the full article on Seeking Alpha
Expanding Patient Reach And Pipeline Development Will Unlock Potential
Strong AYVAKIT demand, expanded market reach, and improved therapy duration fuel revenue growth and enhance operating margin stability.Blueprint Medicines: Strong Business, Ambitious Targets, Expensive Stock
Summary Blueprint Medicines' primary revenue driver is Ayvakit, approved for various forms of Systemic Mastocytosis (SM) and showing strong growth, with 2024 revenues at $479m. The company projects Ayvakit to reach $2 billion in annual revenues by 2030, with significant growth potential as only 10% of the diagnosed SM market is penetrated. Blueprint is developing next-generation drugs like elenestinib and BLU-808, which could further enhance its SM franchise and diversify its revenue streams. Despite impressive growth and a strong cash position, I recommend a "hold" due to the stock's high valuation and the need for pipeline drugs to be further derisked. Read the full article on Seeking AlphaBlueprint Medicines: Growth For The Long Term Still Mostly Priced In
Summary Despite solid earnings beats, Blueprint Medicines is trading down ~16% since my last article. AYVAKIT/AYVAKYT revenues have doubled for four consecutive years, with 2024 guidance pegging net product revenue at $435-$450 million, a ~117% increase from 2023. CEO Haviland highlights AYVAKIT's multibillion-dollar potential, driven by its unique value proposition and strong adoption among physicians, patients, and payers. Blueprint's revised revenue guidance is based on strong first-half 2024 performance and growing experience with factors driving its business, particularly in systemic mastocytosis treatment. Read the full article on Seeking AlphaBlueprint Medicines: Overdue For A Breather
Summary Today, we take a look at Blueprint Medicines Corporation, a company focused on developing precision therapies for cancers and blood disorders. Blueprint's Q1 results were spectacular, and the company has a solid balance sheet, but the stock is up more than 150% from its lows in late October. Can the shares rally further, or are they overdue for a breather? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaBlueprint Medicines: Rampant Growth Mostly Priced In
Summary Blueprint Medicines generates growing revenues from its FDA-approved product AYVAKIT/AYVAKYT. AYVAKIT has been approved for multiple indications, including gastrointestinal stromal tumor and systemic mastocytosis. Blueprint reported strong Q1 2024 earnings, achieving $92.5 million in AYVAKIT net product revenues and raising guidance for full-year revenues. Read the full article on Seeking AlphaBlueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Summary Blueprint Medicines' Ayvakit shows strong performance in the ISM market, with revenue projections increased to $2 billion. Q4 '23 earnings highlight significant growth, with Ayvakit driving revenues up and a strong cash position despite a high burn rate. Market sentiment is robust, supported by strong analyst projections, institutional interest, and stock momentum. I am upgrading my rating to a "strong buy," considering Ayvakit's market potential, financial health, and Blueprint's strategic positioning despite biotech investment risks. Read the full article on Seeking AlphaAnálisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$156m |
| Dec 31 2024 | US$13m | US$821k | -US$67m |
| Sep 30 2024 | n/a | n/a | -US$128m |
| Jun 30 2024 | n/a | n/a | -US$205m |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$6m | US$782k | -US$507m |
| Sep 30 2023 | n/a | n/a | -US$555m |
| Jun 30 2023 | n/a | n/a | -US$554m |
| Mar 31 2023 | n/a | n/a | -US$581m |
| Dec 31 2022 | US$6m | US$701k | -US$558m |
| Sep 30 2022 | n/a | n/a | -US$718m |
| Jun 30 2022 | n/a | n/a | -US$702m |
| Mar 31 2022 | n/a | n/a | -US$650m |
| Dec 31 2021 | US$4m | US$501k | -US$644m |
| Sep 30 2021 | n/a | n/a | -US$411m |
| Jun 30 2021 | n/a | n/a | US$340m |
| Mar 31 2021 | n/a | n/a | US$325m |
| Dec 31 2020 | US$2m | US$461k | US$314m |
| Sep 30 2020 | n/a | n/a | US$333m |
| Jun 30 2020 | n/a | n/a | -US$395m |
| Mar 31 2020 | n/a | n/a | -US$371m |
| Dec 31 2019 | US$3m | US$432k | -US$348m |
| Sep 30 2019 | n/a | n/a | -US$362m |
| Jun 30 2019 | n/a | n/a | -US$340m |
| Mar 31 2019 | n/a | n/a | -US$267m |
| Dec 31 2018 | US$3m | US$393k | -US$237m |
Compensación vs. Mercado: La compensación total de Kate($USD13.48M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD8.38M).
Compensación vs. Ingresos: La compensación de Kate ha aumentado mientras la empresa no es rentable.
CEO
Kate Haviland (49 yo)
Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 3.3yrs | US$13.48m | 0.11% $ 9.1m | |
| Co-Founder & Director | no data | US$549.69k | 0.11% $ 9.6m | |
| Chief Financial Officer | 9.4yrs | US$4.19m | 0.067% $ 5.6m | |
| Chief Operating Officer | 3.3yrs | US$6.54m | 0.032% $ 2.7m | |
| Chief Scientific Officer | 4.2yrs | US$5.13m | 0.082% $ 6.9m | |
| President of Research & Development | 4.8yrs | US$5.50m | 0.049% $ 4.1m | |
| Senior Vice President of Finance and Principal Accounting Officer | no data | sin datos | 0.026% $ 2.2m | |
| Senior Director & Head of Investor Relations | no data | sin datos | sin datos | |
| Executive VP | 8.8yrs | US$2.34m | 0.057% $ 4.8m | |
| Chief People Officer | 5.4yrs | sin datos | 0.035% $ 3.0m | |
| Senior Vice President of Corporate Affairs | no data | sin datos | sin datos | |
| Chief Medical Officer | 5.2yrs | sin datos | 0.047% $ 3.9m |
Equipo directivo experimentado: El equipo directivo de BPMC es experimentado (5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 3.3yrs | US$13.48m | 0.11% $ 9.1m | |
| Co-Founder & Director | 14.3yrs | US$549.69k | 0.11% $ 9.6m | |
| Chair of Scientific Advisory Board | 13.2yrs | US$333.38k | sin datos | |
| Lead Independent Director | 9.3yrs | US$606.19k | 0.020% $ 1.7m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board & Independent Director | 14.3yrs | US$569.69k | 0.086% $ 7.2m | |
| Independent Director | 9.4yrs | US$572.59k | 0.0035% $ 289.6k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3.6yrs | US$574.69k | 0.017% $ 1.4m | |
| Chairman of the Board of Director | 11yrs | US$586.19k | 0.22% $ 18.7m |
Junta con experiencia: Los miembros de la junta directiva de BPMC son experimentados ( 10.2 años antigüedad media).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2025/07/17 06:24 |
| Precio de las acciones al final del día | 2025/07/17 00:00 |
| Beneficios | 2025/03/31 |
| Ingresos anuales | 2024/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Blueprint Medicines Corporation está cubierta por 10 analistas. 19 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| George Farmer | BMO Capital Markets Equity Research |
| Dane Leone | BTIG |
| Arlinda Lee | Canaccord Genuity |